Prognosis of schizophrenia in persons with and without a history of cannabis use

Psychological Medicine

Volumn 44, Issue 12, 2014, Pages 2513-2521

  Manrique Garcia, E ^a   Zammit, S ^b   Dalman, C ^a   Hemmingsson, T ^a,c   Andreasson, S ^a   Allebeck, P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Cannabis; prognosis; psychosis; schizophrenia

Indexed keywords

CANNABIS;

CHEMICALLY INDUCED; FOLLOW UP; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; PROGNOSIS; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA; SWEDEN;

CANNABIS; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; SCHIZOPHRENIA; SWEDEN;

EID: 84904961992     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714000191     Document Type: Article

References (33)

1. Allebeck P, Adamsson C, Engstrom A, Rydberg U. (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 88, 21-24. (Pubitemid 23199896)
2. An der Heiden W, Hafner H. 2000). The epidemiology of onset and course of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 250 292-303. (Pubitemid 32002383)
3. Andreasson S, Allebeck P, Engstrom A, Rydberg U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet ii, 1483-1486.
4. Andreasson S, Allebeck P, Rydberg U. (1989). Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatrica Scandinavica 79, 505-510. (Pubitemid 19153695)
5. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. British Journal of Psychiatry 187, 510-515. (Pubitemid 41752739)
6. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal 325, 1212-1213. (Pubitemid 35398785)
7. Benson G, Holmberg MB. (1985). Validity of questionnaires in population studies on drug use. Acta Psychiatrica Scandinavica 71, 9-18. (Pubitemid 15185537)
8. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. (2009). Psychiatric comorbidities and schizophrenia. Schizophrenia Bulletin 35, 383-402.
9. Castagnini A, Berrios GE. (2009). Acute and transient psychotic disorders (ICD-10 F23): A review from a European perspective. European Archives of Psychiatry and Clinical Neuroscience 259, 433-443.
10. Castle DJ, Sham PC, Wessely S, Murray RM. (1994). The subtyping of schizophrenia in men and women: A latent class analysis. Psychological Medicine 24, 41-51. (Pubitemid 24083680)
11. Coldham EL, Addington J, Addington D. (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106, 286-290.
12. Dalman C, Broms J, Cullberg J, Allebeck P. (2002). Young cases of schizophrenia identified in a national inpatient register-Are the diagnoses valid?. Social Psychiatry and Psychiatric Epidemiology 37, 527-531. (Pubitemid 36097281)
13. Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, Sedvall GC, Jonsson EG. (2005). Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nordic Journal of Psychiatry 59, 457-464. (Pubitemid 41801793)
14. Ferdinand RF, Sondeijker F, Van der Ende J, Selten JP, Huizink A, Verhulst FC. (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100, 612-618. (Pubitemid 40646286)
15. Fergusson DM, Horwood LJ, Swain-Campbell NR. (2003). Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 33, 15-21. (Pubitemid 36113396)
16. Foti DJ, Kotov R, Guey LT, Bromet EJ. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry 167, 987-993.
17. Hall W, Degenhardt L. (2009). Adverse health effects of non-medical cannabis use. Lancet 374, 1383-1391.
18. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, Van Os J. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11.
19. Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, Lane A, Larkin C, OCallaghan E. (2006). A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 21, 29-33. (Pubitemid 43243050)
20. Lachin JM. (2011). Analysis of count data. In Biostatistical Methods: The Assessment of Relative Risks, pp. 381-427. John Wiley and Sons: Chichester.
21. Lewis G, David AS, Malmberg A, Allebeck P. (2000). Non-psychotic psychiatric disorder and subsequent risk of schizophrenia. Cohort study. British Journal of Psychiatry 177, 416-420.
22. Marshall M, Rathbone J. (2011). Early intervention for psychosis. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD004718. doi:10.1002/14651858.CD004718.pub3.
23. Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. (2009). A prospective study of cannabis use as a risk factor for non-Adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 113, 138-144.
24. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
25. Otto U. (1980). Function of male youths during military service. A follow-up study of a youth clientele. Acta Psychiatrica Scandinavica (Suppl.) 282, 1-60.
26. Pomarol-Clotet E, Salvador R, Murray G, Tandon S, McKenna PJ. (2010). Are there valid subtypes of schizophrenia?. A grade of membership analysis. Psychopathology 43, 53-62.
27. Remschmidt H, Theisen F. (2012). Early-onset schizophrenia. Neuropsychobiology 66, 63-69.
28. Rosen JL, Miller TJ, DAndrea JT, McGlashan TH, Woods SW. (2006). Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophrenia Research 85, 124-131. (Pubitemid 43947540)
29. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 156, 319-327. (Pubitemid 34857999)
30. Van Os J, Kapur S. (2009). Schizophrenia. Lancet 374, 635-645.
31. Zalewski C, Johnson-Selfridge MT, Ohriner S, Zarrella K, Seltzer JC. (1998). A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients. Schizophrenia Bulletin 24, 127-145. (Pubitemid 28128494)
32. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. British Medical Journal 325, 1199.
33. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. British Journal of Psychiatry 193, 357-363.